Tax thread runs through pharma deals

Apr 07, 2014

“Even before the Treasury proposals were announced, there was a huge amount of interest in doing these deals because they can create millions in cost savings.”

- Christopher Cox, co-chair of Cadwalader’s Corporate Group, commenting in the Financial Times regarding the surge in “inversions,” whereby a company uses an overseas transaction to relocate its headquarters, since the U.S. government revealed plans to tighten the rules allowing U.S. companies to re-domicile their tax base. Cox, who advised Ireland’s Elan on its $8.6 billion inversion deal with Perrigo last year, added, however, that the pace of enquiries by U.S. companies has stepped up markedly in the past six weeks.

Cadwalader News

ACI Summit on Controlled Substances: Regulation, Litigation and Enforcement

Jodi Avergun is speaking at this ACI event on January 30 in Washington, DC.

Cadwalader Subscription Center